Drugs / nafcillin

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansion US (FDA) UNIPEN 1985-09-05 fda.gov
Approved US (FDA) UNIPEN 1965-10-11 fda.gov

Trials 2 · a red edge is where a trial was stopped

1964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05001750 Jun 2021 → Jun 2026 overdue cerebritis, hydrocephalus, intracerebral hemorrhage, subarachnoid hemorrhage Montefiore Medical Center Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT07376889 Feb 2026 → Jan 2029 expected staphylococcus aureus infection Intermountain Health Care, Inc. Not yet recruiting No outcome recorded
Also used as a comparator or background therapy in 14 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT02099240 Comparator Mar 2014 → Nov 2018 osteomyelitis University of Louisville Terminated No outcome recorded
Phase 27 trials
Phase 2 NCT04775953 Comparator Apr 2021 → Oct 2023 staphylococcal infection National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT01756924 Comparator Dec 2012 → Jul 2014 periprosthetic joint infection Arrevus Inc. Terminated No outcome recorded
Phase 2 NCT00428844 Comparator Jun 2007 → Mar 2010 osteomyelitis Merck & Co., Inc. Completed No outcome recorded
Phase 2 NCT00303589 Comparator Dec 2005 → Oct 2007 Hoffmann-La Roche Completed No outcome recorded
Phase 2 NCT00077675 Comparator Feb → Sep 2004 gram-positive bacterial infections Cumberland Pharmaceuticals Completed No outcome recorded
Phase 33 trials
Phase 3 NCT02344511 Comparator Mar 2016 → Oct 2018 osteomyelitis Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) Withdrawn No outcome recorded
Phase 3 NCT02208063 Comparator Dec 2014 → Apr 2018 bacterial infectious disease Cumberland Pharmaceuticals Terminated No outcome recorded
Phase 3 NCT01922011 Comparator Sep 2013 → Jun 2016 osteomyelitis Merck & Co., Inc. Completed No outcome recorded
Phase 43 trials
Phase 4 NCT07148960 Comparator Sep 2025 → Jul 2027 expected staphylococcus aureus infection West Virginia University Enrolling by invitation No outcome recorded
Phase 4 NCT01104662 Comparator Apr 2010 → Jun 2012 impaired renal function disease, staphylococcus aureus infection Merck & Co., Inc. Terminated No outcome recorded
Phase 4 NCT00711802 Comparator Jul 2008 → Oct 2013 skin disease caused by bacterial infection Merck & Co., Inc. Completed No outcome recorded

Evidence & citations 18 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as nafcillin “Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up...” NCT00061633
15

nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.” NCT00077675

“Intravenous anti-staphylococcal beta-lactam, either cefazolin or nafcillin, per the discretion of the treating physician.” NCT07376889

“Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin.” NCT07148960

Nafcillin 1-2 grams every 6 hours (depending on weight) until the EVD is removed.” NCT05001750

“PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin” NCT00303589

“penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin)” NCT01104662

nafcillin, oxacillin, cloxacillin” NCT00711802

NafcillinNCT02208063

NafcillinNCT02099240

NCT00062647

NCT00428844

NCT01756924

NCT02344511

NCT04775953

NCT01922011

Known as Anhydrous nafcillin sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcil ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcilina ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as NAFCILLIN SODIUM ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcillin sodium anhydrous ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcillin sodium monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcillin sodium salt anhydrous ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcillin sodium salt monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nafcilline ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Nallpen ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as NSC-757108 ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Sodium nafcillin ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Sodium nafcillin monohydrate ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as Unipen ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Known as WY-3277 ChEMBL registry synonym — accepted as the source's own label CHEMBL1443
Modality Small molecule “semi-synthetic antibiotic related to penicillin” NCT04775953
Route Intravenous “nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs” NCT00061633